Get the Stockscreener App
5.98
4.23%
-0.29
Compass Therapeutics Inc stock is traded at $5.98, with a volume of 954.66K.
It is down -4.23% in the last 24 hours and up +16.83% over the past month.
Compass Therapeutics Inc is a clinical-stage biopharmaceutical company that develops proprietary antibody therapeutics to engage the immune system to treat solid tumors and hematological malignancies. It is engaged in drug discovery by leveraging its proprietary antibody discovery engine to drug the immune system and identify optimal combinations empirically broadly. Through StitchMabs and common light chain platforms, these combinatorial insights can be rapidly translated into tailored bispecifics with monoclonal-like manufacturability. Its pipeline is comprised of the following product candidates; CTX-009, CTX-471, CTX-10726, VEGF-IO Bispecific, and CTX-8371.
See More
Previous Close:
$6.27
Open:
$6.25
24h Volume:
954.66K
Relative Volume:
0.44
Market Cap:
$1.07B
Revenue:
-
Net Income/Loss:
$-45.44M
P/E Ratio:
-17.09
EPS:
-0.35
Net Cash Flow:
$-42.28M
1W Performance:
+5.35%
1M Performance:
+16.83%
6M Performance:
+80.33%
1Y Performance:
+93.71%
1-Day Range:
$5.99
$6.35
1-Week Range:
$5.50
$6.40
52-Week Range:
$1.33
$6.40
Compass Therapeutics Inc Stock (CMPX) Company Profile
Name
Compass Therapeutics Inc
Sector
Industry
Phone
617-500-8099
Address
80 GUEST STREET, BOSTON
Compare CMPX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CMPX
Compass Therapeutics Inc
|
5.99 | 1.12B | 0 | -45.44M | -42.28M | -0.35 |
|
VRTX
Vertex Pharmaceuticals Inc
|
463.63 | 118.58B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
749.34 | 79.40B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
811.57 | 51.18B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
360.84 | 48.88B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
339.19 | 37.49B | 4.98B | 69.59M | 525.67M | 0.5197 |
Compass Therapeutics Inc Stock (CMPX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-05-26 | Initiated | William Blair | Outperform |
| Dec-03-25 | Initiated | Canaccord Genuity | Buy |
| Dec-03-25 | Initiated | Cantor Fitzgerald | Overweight |
| Dec-03-25 | Initiated | Citizens JMP | Mkt Outperform |
| Jul-01-25 | Resumed | Raymond James | Outperform |
| Apr-02-25 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Feb-24-25 | Initiated | Guggenheim | Buy |
| Feb-19-25 | Initiated | Piper Sandler | Overweight |
| Dec-23-24 | Initiated | D. Boral Capital | Buy |
| Nov-15-24 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Sep-16-24 | Upgrade | Ladenburg Thalmann | Neutral → Buy |
| Jan-31-23 | Initiated | Jefferies | Buy |
| Jan-27-23 | Initiated | Stifel | Buy |
| May-23-22 | Resumed | H.C. Wainwright | Buy |
| Mar-15-22 | Initiated | Ladenburg Thalmann | Buy |
| Jan-19-22 | Initiated | B. Riley Securities | Buy |
| Dec-22-21 | Initiated | Raymond James | Outperform |
| Dec-20-21 | Initiated | SVB Leerink | Outperform |
| Dec-15-21 | Initiated | Wedbush | Outperform |
View All
Compass Therapeutics Inc Stock (CMPX) Latest News
Compass Therapeutics stock hits 52-week high at 6.25 USD By Investing.com - Investing.com Nigeria
Compass Therapeutics (NASDAQ:CMPX) Hits New 12-Month HighHere's What Happened - MarketBeat
Compass Therapeutics stock hits 52-week high at 6.25 USD - Investing.com
Compass Therapeutics: Exciting Clinical Updates Inbound For 2026, But Don't Get Too Ahead - Seeking Alpha
Compass Therapeutics, Inc. (CMPX): A Bull Case Theory - Finviz
Is Compass Therapeutics Inc. stock a defensive play in 2025Weekly Investment Summary & Reliable Price Breakout Signals - bollywoodhelpline.com
How Compass Therapeutics Inc. stock reacts to global recession fearsJuly 2025 Analyst Calls & Real-Time Volume Analysis - bollywoodhelpline.com
Compass Therapeutics (NASDAQ:CMPX) Rating Lowered to "Sell" at Wall Street Zen - MarketBeat
Assessing Compass Therapeutics (CMPX) Valuation After Strong 1 Year Share Price Performance - Yahoo Finance
Assessing Compass Therapeutics (CMPX) Valuation After A Year Of Strong Share Price Momentum - Sahm
Aug Catalysts: How does Compass Therapeutics Inc perform in inflationary periods2025 Buyback Activity & Risk Managed Trade Strategies - baoquankhu1.vn
Is Compass Therapeutics (CMPX) Quietly Rewriting Its Oncology Strategy With New Commercial and Medical Chiefs? - Yahoo Finance
Compass Therapeutics (NASDAQ:CMPX) Trading Down 6.8%Time to Sell? - MarketBeat
Will Compass Therapeutics’ (CMPX) New Oncology Leaders Redefine Its Path From Pipeline to Commercial Scale? - Sahm
Compass Therapeutics (NASDAQ:CMPX) Sets New 12-Month HighTime to Buy? - MarketBeat
Compass Therapeutics Inc. (CMPX) is A Buy on Wall Street on Robust Pipeline Development - MSN
Growth Review: Is Compass Therapeutics Inc stock a top pick in earnings seasonJuly 2025 Summary & Community Consensus Trade Alerts - Bộ Nội Vụ
Strong Analyst Confidence in Compass Therapeutics (CMPX) Driven by CTX-10726 Advancement - MSN
Lifesci Capital Has Strong Estimate for CMPX FY2025 Earnings - Defense World
What is Lifesci Capital's Estimate for CMPX FY2025 Earnings? - MarketBeat
Why Compass Therapeutics Inc. stock could outperform in 2025Market Trend Report & Scalable Portfolio Growth Ideas - Улправда
Will Compass Therapeutics Inc. stock benefit from green energy trendsQuarterly Profit Summary & Low Drawdown Momentum Ideas - ulpravda.ru
Is Compass Therapeutics Inc. stock affected by interest rate hikesJuly 2025 Rallies & Capital Protection Trading Alerts - Улправда
Short Squeeze: Is Compass Therapeutics Inc. stock supported by strong fundamentalsWeekly Trade Review & Daily Volume Surge Signals - ulpravda.ru
Will Compass Therapeutics Inc. stock benefit from commodity prices2025 Fundamental Recap & Weekly Breakout Watchlists - Улправда
Is Compass Therapeutics Inc. stock supported by strong fundamentals2025 Technical Patterns & Free Expert Verified Stock Movement Alerts - Улправда
Compass Therapeutics, Inc. (CMPX) Stock Analysis: Exploring a Biotech Powerhouse with 142.77% Upside Potential - DirectorsTalk Interviews
Why analysts remain bullish on Compass Therapeutics Inc. stock2025 Investor Takeaways & Reliable Entry Point Alerts - ulpravda.ru
Is Compass Therapeutics Inc. stock in correction or buying zoneMarket Capitalization Trends & Reinvest for Maximum Compounding Returns - Улправда
Monte Rosa Therapeutics, Ventyx Biosciences, United Microelectronics And Other Big Stocks Moving Higher On Wednesday - Benzinga
Compass Therapeutics stock rating reiterated at Market Outperform by Citizens - Investing.com Canada
Compass Therapeutics details cash runway and pipeline progress - MSN
Compass Therapeutics (NASDAQ:CMPX) Receives “Buy” Rating from D. Boral Capital - Defense World
Compass Therapeutics appoints new chief commercial and medical officers By Investing.com - Investing.com Nigeria
Stifel reiterates Buy rating on Compass Therapeutics stock with $12 target - Investing.com Canada
Raymond James reiterates Outperform rating on Compass Therapeutics stock By Investing.com - Investing.com Canada
Compass Therapeutics' (CMPX) "Buy" Rating Reaffirmed at D. Boral Capital - MarketBeat
Compass Therapeutics reports progress across cancer drug pipeline By Investing.com - Investing.com South Africa
Compass Therapeutics Provides Corporate Update - The Manila Times
Compass Therapeutics reports progress across cancer drug pipeline - Investing.com
CMPXCompass Therapeutics Inc Latest Stock News & Market Updates - Stock Titan
Compass Announces Inducement Grants Under Nasdaq Listing Rule 5635 - Investing News Network
Compass Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Compass Therapeutics, Inc. Announces Executive Appointments, Effective as of January 1, 2026 - marketscreener.com
William Blair Initiates Coverage of Compass Therapeutics (CMPX) with Outperform Recommendation - Nasdaq
Compass Therapeutics' Bile Duct Cancer Drug Seen As New Standard Of Care - One News Page
Compass Therapeutics announces key leadership appointments - marketscreener.com
Compass Therapeutics appoints new chief commercial and medical officers - Investing.com
Compass Therapeutics Announces Key Leadership Appointments - The Manila Times
William Blair Initiates Compass Therapeutics at Outperform - MarketScreener
William Blair initiates coverage on Compass Therapeutics stock with Outperform rating - Investing.com Canada
Compass Therapeutics Inc Stock (CMPX) Financials Data
Revenue
Net Income
Cash Flow
EPS
4.38%
1.95%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):